Log In
BCIQ
Print this Print this
 

RG6146 (formerly TEN-010)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSmall molecule bromodomain inhibitor that is selective for the bromodomain and extra-terminal domain (BET) protein family (BRD4, BRD3, BRD2 and BRDT)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors in patients refractory or intolerant to standard/approved therapies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$535.0M

$115.0M

$420.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$535.0M

$115.0M

$420.0M

Get a free BioCentury trial today